AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

A federal judge threw out Amgen’s lawsuit against the state board empowered to set first-in-the-nation price ceilings on prescription drugs in Colorado, finding that the maker of arthritis medication ...

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...